WASHINGTON – The United States put Canada on the “watch list” of countries where its policies and practices can be a threat to American intellectual property rights.
In its annual report on foreign dangers to American rights holders, the US Trade Representative’s office raises concerns about Canada’s plan to recalibrate how it calculates prescription drug prices.
However, the report did not meet the demands of the U.S. pharmaceutical industry. Canada to be raised to the list of USTR “priority” problems.
The Liberal federal government announced last summer that the Medicines Price Agency patented along the arm would stop using drug prices in the US and Switzerland – among the highest in the world – to help determine what Canadian patients should pay.
American Pharmaceutical Research and Manufacturers, a drug industry lobbying group, said Canada’s plan would be an obstacle to efforts to develop new treatments and would ultimately devalue American-patented medicines.
This week’s USTR report does not recognize future intellectual property reforms in the new North American trade agreement, but calls on Canada to “contribute fairly” to the research and development of innovative medicines.
The Canadian Press report was first published May 1 2020.
to request modification Contact us at Here or [email protected]